221 related articles for article (PubMed ID: 21138845)
1. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.
Pirie CM; Hackel BJ; Rosenblum MG; Wittrup KD
J Biol Chem; 2011 Feb; 286(6):4165-72. PubMed ID: 21138845
[TBL] [Abstract][Full Text] [Related]
2. Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin.
Pirie CM; Liu DV; Wittrup KD
Mol Cancer Ther; 2013 Sep; 12(9):1774-82. PubMed ID: 23832121
[TBL] [Abstract][Full Text] [Related]
3. Cell-targeting fusion constructs containing recombinant gelonin.
Lyu MA; Cao YJ; Mohamedali KA; Rosenblum MG
Methods Enzymol; 2012; 502():167-214. PubMed ID: 22208986
[TBL] [Abstract][Full Text] [Related]
4. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
[TBL] [Abstract][Full Text] [Related]
5. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
7. Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.
Kornberger P; Skerra A
MAbs; 2014; 6(2):354-66. PubMed ID: 24492291
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
[TBL] [Abstract][Full Text] [Related]
9. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.
Rosenblum MG; Cheung L; Kim SK; Mujoo K; Donato NJ; Murray JL
Cancer Immunol Immunother; 1996 Feb; 42(2):115-21. PubMed ID: 8620520
[TBL] [Abstract][Full Text] [Related]
10. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of cellular trafficking and cytotoxicity of 9.2.27-gelonin immunotoxins targeted against the high-molecular-weight melanoma-associated antigen.
Chan MC; Murphy RM
Cancer Immunol Immunother; 1999 Feb; 47(6):321-9. PubMed ID: 10203062
[TBL] [Abstract][Full Text] [Related]
12. Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor.
Ozawa S; Ueda M; Ando N; Abe O; Minoshima S; Shimizu N
Int J Cancer; 1989 Jan; 43(1):152-7. PubMed ID: 2783415
[TBL] [Abstract][Full Text] [Related]
13. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis.
Goldmacher VS; Scott CF; Lambert JM; McIntyre GD; Blättler WA; Collnhson AR; Stewart JK; Chong LD; Cook S; Slayter HS
J Cell Physiol; 1989 Oct; 141(1):222-34. PubMed ID: 2528553
[TBL] [Abstract][Full Text] [Related]
15. A gelonin-containing immunotoxin directed against human breast carcinoma.
Rosenblum MG; Zuckerman JE; Marks JW; Rotbein J; Allen WR
Mol Biother; 1992 Sep; 4(3):122-9. PubMed ID: 1445665
[TBL] [Abstract][Full Text] [Related]
16. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
17. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
18. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
Wiels J; Junqua S; Dujardin P; Le Pecq JB; Tursz T
Cancer Res; 1984 Jan; 44(1):129-33. PubMed ID: 6690030
[TBL] [Abstract][Full Text] [Related]
19. Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy.
Polli JR; Chen P; Bordeau BM; Balthasar JP
AAPS J; 2022 Mar; 24(3):47. PubMed ID: 35338415
[TBL] [Abstract][Full Text] [Related]
20. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]